| Needs
Assessment
Through needs assessment surveys, literature searches, advisory
board suggestions, and recent specialty publications, ImproMED
has identified that a need exists to educate ophthalmologists
on current glaucoma treatment options and practices. Issues
surrounding safety and efficacy of the various glaucoma
treatment options have been examined in recent clinical
trials, and have led to the reconsideration of current treatment
strategies for glaucoma patients.
Target
Audience
General ophthalmologists and those with a subspecialty in
Glaucoma.
Overall
Purpose
The purpose of this activity is to provide ophthalmologists
with a thorough understanding of the safety and efficacy
profiles involved with various glaucoma treatment options.
Educational Objectives
Upon completion of this CME activity, participants should
have increased overall skills, knowledge, attitudes, and
performance, with a specific ability to:
Skill(s)
Identify the different classes of medications used to
treat glaucoma, and discern their various mechanisms of
action
Knowledge
Compare the safety and efficacy profiles for glaucoma
treatment options
Recognize which patients are likely to benefit most from
early glaucoma treatment, based on an assessment of demographic
and clinical risk factors
Discuss rationale of first-line therapy choices: medication
and surgery
Attitude(s)
Consider the effects that the choice of therapy has on
the patient (cost, compliance, convenience, quality of
life)
Performance
Examine recent advances made in the treatment of glaucoma
and consider how these impact clinical practice
Designation of Credit Statement
ImproMED designates this educational activity for a maximum
of 1.0 category 1 credit toward the AMA Physician’s
Recognition Award. Each physician should claim only those
credits that he/she actually spent in the activity.
Disclosure Policy
It is the policy of ImproMED to ensure balance, independence,
objectivity, and scientific rigor in all its sponsored educational
activities. All faculty are expected to disclose to program
audiences any significant relationships related to the content
of their presentations.
Unapproved
uses of drug regimens may be discussed.
 Activity
Review Committee
This activity was reviewed by Richard
K. Parrish II, MD, Activity Chair,
James Spindler,
MD, and Suzanne
Eggers.
Term of Approval: December 2003 through December 2004.
The certification periods for the following activities have expired, but the programs remain available for viewing. Please note that your participation in these activities is not eligible for AMA PRA category 1 credit, but may be eligible for AMA PRA category 2 credit. Please contact ImproMED with questions (seggers@impromed.org or 269.329.0651 x31) or view the AMA guidelines for PRA credit at http://www.ama-assn.org/ama/pub/category/2938.html.
|
